US FDA snubs Merck's ezetimibe/atorvastatin combo statin pill
This article was originally published in Scrip
Executive Summary
Merck failed to convince the US FDA to approve the pharma giant's ezetimibe-atorvastatin combo statin pill, known as MK-0653C, as a treatment for primary or mixed hyperlipidemia, the company revealed on 5 March, noting that regulators said additional data will be needed before the experimental medication can enter the marketplace.